8-K: Lineage Partners with WDI for Hearing Loss Cell Therapy

Lineage Cell Therapeutics announced a multi-year research collaboration with William Demant Invest to advance its ReSonance program for hearing loss, with WDI funding up to $12 million.

Summary

• Lineage Cell Therapeutics entered into a multi-year research collaboration agreement with William Demant Invest 2 Aps (WDI).
• The collaboration aims to advance the preclinical development of Lineage's auditory neuronal cell transplant program, ReSonance™ (ANPI), for the treatment of hearing loss.
• WDI will fund up to $12 million in research collaboration costs over the approximate three-year term of the agreement.
• The primary objective is to complete a preclinical phase, preparing the program for potential progression to human clinical trials under separate clinical agreements.
• Development activities will be jointly conducted and managed by Lineage and scientists from Eriksholm Research Centre, a subsidiary of the Demant Group.
• Intellectual property generated from the project (Project Results) will be jointly owned, excluding discoveries related to Lineage's proprietary platform technology.
• If a party withdraws from the collaboration, the continuing party may purchase the abandoning party's ownership interest in the Project IP for hearing loss exploitation.

Sentiment

Score: 8

Explanation: The announcement of a significant research collaboration with a well-regarded industry partner (William Demant Invest) and substantial non-dilutive funding ($12 million) for a promising preclinical program (ReSonance) is a strong positive. It validates Lineage's platform and provides resources for advancing a new therapeutic candidate in an area of high unmet medical need. While preclinical, the partnership significantly de-risks early development and provides a clear path forward.

Positives

• Secured up to $12 million in non-dilutive funding from WDI for the ReSonance (ANPI) program's preclinical development.
• Partnership with WDI, an evergreen investor with strong interest and expertise in hearing healthcare through Demant A/S and Eriksholm Research Centre.
• Leverages Lineage's proprietary cell-based technology platform and manufacturing capabilities, demonstrating platform efficiency.
• Advances ReSonance, Lineage's first internally-developed cell transplant program, addressing a significant unmet medical need.
• Collaboration integrates specialized hearing loss research expertise with Lineage's cell transplant and manufacturing expertise.
• The agreement outlines a clear path towards potential Investigational New Drug (IND) or Clinical Trial Application (CTA) filing and subsequent human clinical trials.

Negatives

• The funding is specifically for preclinical development and does not guarantee successful progression to clinical trials or commercialization.
• Future clinical agreements and their terms still need to be negotiated in good faith.
• Joint ownership of Project Results could lead to complexities if one party decides not to continue.
• The program is still in early preclinical stages, implying a long development timeline and significant future investment requirements beyond WDI's initial contribution.

Risks

• Development activities, preclinical activities, and clinical trials of product candidates may not commence, progress, or be completed as expected due to various factors.
• Positive findings in early clinical and/or nonclinical studies may not be predictive of success in subsequent studies.
• The ongoing Israeli regional conflict may materially and adversely impact manufacturing processes, including cell banking and product manufacturing, as these are conducted by Lineage's subsidiary in Jerusalem, Israel.
• Lineage may not be able to manufacture sufficient clinical quantities of its product candidates in accordance with current good manufacturing practice.
• General risks and uncertainties inherent in Lineage's business and other risks discussed in Lineage's periodic reports with the SEC.

Future Outlook

The collaboration aims to advance the ReSonance (ANPI) program through preclinical development over approximately three years, with the main objective of achieving readiness to potentially progress to human clinical trials under one or more separate clinical agreements to be negotiated in good faith before the RCA's expiration. The activities are intended to support a potential IND/CTA filing.

Management Comments

• "ReSonance is our first internally-developed cell transplant program and highlights the efficiency and breadth of our technology platform." Brian Culley, Lineage CEO.
• "Over a short period of time and with a modest initial, incremental investment, we advanced the ANP1 product concept through successful manufacture of the desired cell type, generated new intellectual property, and advanced into initial preclinical testing." Brian Culley, Lineage CEO.
• "With this research contribution from WDI, which has a strong interest in hearing healthcare, we are taking the next step in the development of this exciting product candidate." Brian Culley, Lineage CEO.
• "This partnership will allow us to integrate the hearing loss research expertise of Eriksholm Research Centre with the manufacturing and cell transplant expertise of the Lineage team to explore the potential of a differentiated cell transplant, and position this therapy for initial clinical development." Brian Culley, Lineage CEO.

Industry Context

Hearing loss is a significant global health challenge, with the World Health Organization (WHO) projecting nearly 2.5 billion people to experience some degree of hearing loss by 2025. Severe-to-profound cases often involve the loss of auditory nerve cells, leading to conditions like auditory neuropathy, for which current treatment options are limited. Cell-based therapy, such as Lineage's ReSonance program, represents a promising, differentiated approach to replace lost or damaged auditory nerve cells, potentially restoring hearing and enhancing cochlear implant effectiveness. This collaboration with WDI, a major player in hearing healthcare through Demant A/S, positions Lineage to leverage specialized industry expertise and address a critical unmet need.

Stakeholder Impact

• Shareholders: Positive impact due to non-dilutive funding, validation of technology, and advancement of a new pipeline candidate, potentially increasing long-term value.
• Patients: Potential for a novel cell-based therapy to address severe-to-profound hearing loss and auditory neuropathy, offering hope for improved outcomes where current options are limited.
• Employees: Collaboration with Eriksholm Research Centre could foster knowledge exchange and enhance research capabilities.
• Partners (WDI/Demant Group): Strengthens their position in hearing healthcare innovation and provides access to Lineage's cell therapy platform.

Next Steps

• Jointly conduct and manage preclinical development activities for ReSonance (ANPI) over approximately three years.
• Complete preclinical phase to achieve readiness for potential human clinical trials.
• Negotiate terms for one or more separate clinical agreements before the expiration of the RCA.
• Support a potential Investigational New Drug (IND) or Clinical Trial Application (CTA) filing.

Key Dates

Recommendation

The collaboration with William Demant Invest, a strategic partner with deep industry expertise in hearing healthcare, provides Lineage with significant non-dilutive funding of up to $12 million for its ReSonance program. This partnership validates Lineage's proprietary cell therapy platform and de-risks the preclinical development of a promising candidate for a large unmet medical need (hearing loss). For a clinical-stage biotechnology company, securing such a partnership and funding without equity dilution is a strong positive signal, indicating progress and potential for future value creation, warranting a 'buy' recommendation for investors with a long-term horizon and tolerance for biotech risk.

Keywords

Lineage Cell Therapeutics, LCTX, William Demant Invest, WDI, ReSonance, ANPI, Auditory Neuronal Cell Transplant, Hearing Loss, Cell Therapy, Biotechnology, Preclinical Development, Research Collaboration, Demant A/S, Eriksholm Research Centre, Auditory Neuropathy